Topas Therapeutics GmbH

What is the Topas platform?   At Topas Therapeutics, we are pioneering a transformative approach to treating autoimmune and immune-mediated diseases with our proprietary tolerance-inducing platform enabled by our Topas nanoparticles.   Our nanoparticles contain a biocompatible polymer carrying disease-specific antigenic peptides. These particles are the core of our tolerance-inducing platform, and they are engineered to deliver these disease-specific antigenic peptides almost exclusively to liver sinusoidal endothelial cells (LSECs), thereby inducing a powerful anti-inflammatory immune response and steering T cells towards tolerance. This targeted delivery ensures rapid clearance from circulation as well as minimizes systemic and immune reactions.   Topas is committed to leveraging this innovative technology to create disease-modifying treatments that promise a better quality of life for patients. Following the announcement of the positive topline data from our Phase 2a clinical trial in celiac disease, stay tuned as we continue to advance our pipeline and bring transformative solutions to those in need.   🔗 https://lnkd.in/ddryk6zv

Our CEO Hugo Fry met with Plattform Life Sciences' Urs Moesenfechtel at BIO-Europe in Stockholm earlier this month to discuss how we are advancing our innovative Topas nanoparticles to unlock the transformative potential of immune tolerance. Access the full article here to read more about our approach and the recent positive topline data we announced from our Phase 2a study in celiac disease: https://lnkd.in/eVunciXA

Meet the Topas team in London!   Our CEO, Hugo Fry and CBO, Alex Marshall will be in London during the Jefferies London Healthcare Conference from November 19–21.   Following the recent announcement of topline results from our Phase 2a trial of our lead program TPM502 in patients with celiac disease, we look forward to engaging with peers and the investment community to discuss how our innovative platform technology offers the potential to create novel treatment options for patients with autoimmune and immune-driven diseases.   If you are also in London and want to connect with our team, please reach out. We are happy to share more insights on how we are harnessing the liver's power to foster immune tolerance.   #JefferiesHealthcare #CeD #ImmuneTolerance

  Our Chief Medical Officer, Cristina de Min, MD, is featured in the latest Women in STEM series by Drug Target Review.   In the article, Cristina shares her journey from clinical practice to drug development, highlighting her work in early-stage scientific discovery and her contributions to advancing treatments that improve patient outcomes. At Topas Therapeutics, she continues to leverage innovative approaches, like our Topas nanoparticle platform, a new drug modality with the potential to address a broad range of autoimmune and immune-mediated diseases.   Read the full article to learn more about Cristina’s experiences in STEM and her impactful work in the field.   #WomenInSTEM

Topas’ Cristina de Min, MD, Chief Medical Officer, Hugo Fry, Chief Executive Officer, and Alex Marshall, Chief Business Officer, will be attending BIO-Europe 2024 from November 4-6 in Stockholm, Sweden. Following the initial review of the data from our Phase 2a clinical trial announced earlier this week, we look forward to connecting with fellow industry innovators and investors. Cristina, Hugo, and Alex will be available to discuss the programs in our pipeline and our proprietary platform, which targets the underlying causes of a range of autoimmune and immune-mediated diseases, such as celiac disease and type 1 diabetes, with the goal of delivering long-lasting, disease-modifying therapies. If you’re interested in discussing the data in more detail, make sure to set up a meeting with the Topas team through the PartneringONE platform. #BIOEurope24 #BIOEurope2024 #BIOEurope

Today, we are sharing positive topline results from our Phase 2a study evaluating TPM502 in adult patients with celiac disease. The topline study data shows a good safety profile and provides initial proof of concept for our proprietary platform, demonstrating its ability to induce antigen-specific tolerogenic effects that persist. These findings underscore the potential of our platform to address a wide range of autoimmune and immune-mediated diseases. With TPM502 showing a clear dose-response in tolerance induction, we see a significant opportunity for future development. Topas plans to present the full analysis at an upcoming scientific conference. 

For European Biotechnology Week, we are celebrating the biotechnology sector, which has its roots in the discovery of the DNA molecule in 1953. The week aims to raise awareness about the significant contributions of biotechnology. At Topas Therapeutics, we contribute to the biotech sector with our novel antigen-specific and targeted nanoparticle technology. Our proprietary Topas Particle Conjugate (TPC) platform harnesses the natural tolerogenic capabilities of liver sinusoidal endothelial cells (LSECs) to address the underlying causes of autoimmune and immune-driven diseases. Our platform has the potential for developing disease-modifying treatments for conditions such as celiac disease, pemphigus vulgaris, Type 1 diabetes, and multiple sclerosis. As we celebrate the biotechnology sector’s achievements, we take pride in our leadership in harnessing the power of the liver to generate immune tolerance and in developing innovative therapies for autoimmune and antigen-driven diseases. #EuropeanBiotechnologyWeek #BiotechWeek #EBW2024 #EBW24

Last Friday was National Celiac Disease (CeD) Awareness Day, but the need for awareness continues. We stand with the global community in raising awareness about CeD, an autoimmune condition affecting millions worldwide. CeD is often misunderstood, but it is vital to recognize its significance. This serious autoimmune disorder occurs when the ingestion of gluten—a protein found in wheat, barley, and rye—triggers an immune response in the small intestine. This response can damage the intestinal lining, leading to nutrient malabsorption and a range of severe health complications. Currently, management of the disease relies solely on a strict gluten-free diet. As this video from the Celiac Disease Foundation highlights, ongoing research is critical to finding better treatments. At Topas, we are utilizing our highly differentiated and versatile nanoparticle technology platform to develop a broad pipeline of novel therapies to treat autoimmune and antigen-driven diseases, including CeD. We currently have an ongoing Ph2a study in CeD, with results expected later this year. #CeliacDiseaseAwareness #NationalCeliacDiseaseAwarenessDay

We want to extend a warm welcome to Alex Marshall as he joins our Topas team as Chief Business Officer! With over two decades of experience in business development, IP strategy & alliance management in the BioPharma sector, Alex brings a wealth of expertise that will be crucial to our continued growth and success. Alex joins at an exciting time for Topas as we anticipate upcoming data from our phase 2a trial for TPM502 in celiac disease later this year. As Chief Business Officer, Alex will be instrumental in driving strategic partnerships and licensing opportunities as we move forward with our novel immune tolerance technology. His expertise will be invaluable as Topas advances its broad pipeline of therapies to treat autoimmune and antigen-driven diseases. Great to have you on the team, Alex! Learn more about Alex and the Topas team here: https://lnkd.in/e2f_eKEa

Celiac Disease (CeD) is a serious autoimmune disorder triggered by consuming gluten, leading to damage in the small intestine. Affecting an estimated 3.3 million people in the USA, CeD currently has no approved medical treatments; the only management strategy is a strict gluten-free diet. Unfortunately, 30% of patients continue to experience severe symptoms and persistent inflammation despite adhering to this diet. Here’s why addressing this condition is crucial: Work Impact: CeD patients miss approximately 50% more workdays than non-CeD individuals, significantly impacting productivity and quality of life. Cancer Risk: CeD patients are 3-12 times more likely to develop non-Hodgkin’s lymphoma, a life-threatening complication. Severe and Refractory Celiac Disease (RCD): About 130,000 patients in the USA suffer from severe and refractory celiac disease, leading to additional complications such as malabsorption, ulcerative jejunitis, and enteropathy-associated T-cell lymphoma. At Topas Therapeutics, we aim to transform the treatment landscape for CeD by using our proprietary and versatile platform for the generation of highly differentiated, antigen-coupled nanoparticles, Topas Particle Conjugates. Our approach aims to establish immune tolerance, thereby delivering significant therapeutic benefits to patients. Our first study in CeD patients with lead candidate, TPM502, has completed patient recruitment, with data expected in Q3 2024. #CeliacDisease #CeD #ImmuneTolerance